Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

BENOIT C PINEAU

Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology

NPI
1619173309
CMS profile
300169
Location
ST. AUGUSTINE, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$5,633.41

99 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

Page 2 of 2; records 51–99 of 99 matching records. This page contains 49 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

BENOIT C PINEAU

NPI 1619173309 · CMS profile ID 300169

Allopathic & Osteopathic Physicians / Internal Medicine / Gastroenterology

ST. AUGUSTINE, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–99 of 99 matching records. This page contains 49 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1619173309?year=2021&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
BENOIT C PINEAU, NPI 1619173309, CMS profile ID 300169. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–99 of 99 matching records. This page contains 49 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1619173309?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). BENOIT C PINEAU, NPI 1619173309, CMS profile ID 300169. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–99 of 99 matching records. This page contains 49 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1619173309?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
BENOIT C PINEAU, NPI 1619173309, CMS profile ID 300169, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–99 of 99 matching records. This page contains 49 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1619173309?year=2021&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

99 matching records · $5,633.41 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 99 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–99 of 99.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Salix Pharmaceuticals, a division of Bausch Health US, LLC $7.2806/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 850276721 CMS
AbbVie Inc. $2.0206/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795648339 CMS
Janssen Biotech, Inc. $18.9406/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788485047 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $9.2906/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 850387275 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $9.3406/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 850354441 CMS
PFIZER INC. $20.1306/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832626547 CMS
AbbVie Inc. $13.1305/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795648333 CMS
Alfasigma USA, Inc. $17.1805/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 853053345 CMS
Gilead Sciences, Inc. $24.5005/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848259045 CMS
Ambu Inc. $15.7405/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833648645 CMS
Medtronic, Inc. $15.5205/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 815764205 CMS
QOL Medical, LLC $93.6105/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833617897 CMS
Janssen Biotech, Inc. $18.5405/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788485051 CMS
QOL Medical, LLC $19.8905/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833609559 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $15.7905/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 850064077 CMS
Janssen Biotech, Inc. $13.3704/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788485039 CMS
AbbVie Inc. $18.1004/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795648327 CMS
PFIZER INC. $18.7404/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832568832 CMS
AbbVie Inc. $6.3204/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795648321 CMS
Takeda Pharmaceuticals U.S.A., Inc. $15.7204/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 820152133 CMS
Pharming Healthcare, Inc. $20.5004/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 820560249 CMS
Amgen Inc. $24.1904/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825178521 CMS
QOL Medical, LLC $16.8504/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833609557 CMS
PFIZER INC. $35.8404/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832557379 CMS
Takeda Pharmaceuticals U.S.A., Inc. $37.6103/31/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 820152127 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $6.7203/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 850317439 CMS
Janssen Biotech, Inc. $13.3503/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788485049 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $9.8403/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 850182079 CMS
Ironwood Pharmaceuticals, Inc $12.1103/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 855107615 CMS
AbbVie Inc. $16.5903/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795648315 CMS
Janssen Biotech, Inc. $17.0903/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788485059 CMS
Axonics, Inc. $17.2203/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 840588943 CMS
AbbVie Inc. $9.5603/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795648309 CMS
AbbVie Inc. $18.7503/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795648303 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $23.0103/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 850254841 CMS
AbbVie Inc. $4.4503/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795648297 CMS
Amgen Inc. $20.4602/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826528511 CMS
Merck Sharp & Dohme Corporation $15.3002/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848319203 CMS
AbbVie Inc. $14.9902/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795648291 CMS
Janssen Biotech, Inc. $7.8402/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788485037 CMS
Ironwood Pharmaceuticals, Inc $12.3902/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 855113747 CMS
Intercept Pharmaceuticals, Inc. $17.3302/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 836211627 CMS
Janssen Biotech, Inc. $3.6301/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788485045 CMS
Ironwood Pharmaceuticals, Inc $11.2301/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 855128321 CMS
Janssen Biotech, Inc. $12.3401/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788485055 CMS
PFIZER INC. $18.8001/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832614311 CMS
AbbVie Inc. $19.0301/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795648285 CMS
AbbVie Inc. $20.2901/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795648279 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $11.3301/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849983141 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,034.45 49
PY2020 $409.47 24
PY2021 $5,633.41 99
PY2022 $2,060.84 102
PY2023 $2,245.42 116
PY2024 $4,830.93 116
PY2025 $24,515.06 148

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $104,124.38 29
PY2024 Principal investigator $139,873.98 42
PY2023 Principal investigator $101,148.91 17
PY2022 Principal investigator $8,000.00 1

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

29 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $15,300.00 12/17/2025 Non-covered Recipient Entity
Jacksonville Center for Clinical Research
Study of DONQ52 in Active Celiac Disease No dispute reported 06/30/2026 1211617847
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $5,000.00 12/17/2025 Non-covered Recipient Entity
Jacksonville Center for Clinical Research
Study of DONQ52 in Active Celiac Disease No dispute reported 06/30/2026 1211617850
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $2,793.00 12/17/2025 Non-covered Recipient Entity
Jacksonville Center for Clinical Research
Study of DONQ52 in Active Celiac Disease No dispute reported 06/30/2026 1211617855
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $3,948.00 12/17/2025 Non-covered Recipient Entity
Jacksonville Center for Clinical Research
Study of DONQ52 in Active Celiac Disease No dispute reported 06/30/2026 1211617860
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $1,500.00 12/17/2025 Non-covered Recipient Entity
Jacksonville Center for Clinical Research
Study of DONQ52 in Active Celiac Disease No dispute reported 06/30/2026 1211617864
Principal investigator 1 Madrigal Pharmaceuticals $2,523.32 11/25/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248252845
Principal investigator 1 Madrigal Pharmaceuticals $2,189.74 10/16/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248251517
Principal investigator 1 Madrigal Pharmaceuticals $1,567.50 09/18/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248250221
Principal investigator 1 Madrigal Pharmaceuticals $500.00 09/04/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248249504
Principal investigator 1 Madrigal Pharmaceuticals $2,189.74 08/21/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248248862
Principal investigator 1 Madrigal Pharmaceuticals $2,523.32 07/31/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248247730
Principal investigator 1 Madrigal Pharmaceuticals $11,475.00 07/31/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248247733
Principal investigator 1 Madrigal Pharmaceuticals $325.00 07/31/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248247737
Principal investigator 1 Madrigal Pharmaceuticals $10,665.00 07/10/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248246802
Principal investigator 1 Madrigal Pharmaceuticals $175.00 07/10/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248246806
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $15,597.50 07/09/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A STUDY OF TAK-062 IN TREATMENT OF ACTIVE CELIAC DISEASE IN PARTICIPANTS ATTEMPTING A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223282418
Principal investigator 1 Madrigal Pharmaceuticals $2,690.05 05/22/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248244396
Principal investigator 1 Madrigal Pharmaceuticals $1,507.50 05/22/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248244405
Principal investigator 1 Madrigal Pharmaceuticals $1,118.50 04/10/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248242287
Principal investigator 1 Madrigal Pharmaceuticals $622.50 04/10/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248242291
Principal investigator 1 Madrigal Pharmaceuticals $2,189.74 04/08/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248241926
Principal investigator 1 Madrigal Pharmaceuticals $810.00 03/13/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH LTD
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248240914
Principal investigator 1 Madrigal Pharmaceuticals $125.00 03/13/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH LTD
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248240918
Principal investigator 1 Madrigal Pharmaceuticals $5,010.60 03/06/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH LTD
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248240404
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $540.00 03/03/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A STUDY OF TAK-062 IN TREATMENT OF ACTIVE CELIAC DISEASE IN PARTICIPANTS ATTEMPTING A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223275791
Principal investigator 2 Madrigal Pharmaceuticals $1,800.00 02/13/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH LTD
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248239721
Principal investigator 1 Madrigal Pharmaceuticals $1,800.00 02/13/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH LTD
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248239725
Principal investigator 1 Madrigal Pharmaceuticals $5,213.37 02/06/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH LTD
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248239246
Principal investigator 1 AstraZeneca Pharmaceuticals LP $2,425.00 01/29/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEA
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase III Efficacy and Safety Study of Tezepelumab in Patients with Eosinophilic Esophagitis (CROSSING) No dispute reported 06/30/2026 1185547211